Biotech/Health
•1 min read
CSL Strikes $1.6B Co-Development Deal With Alentis for Rare Disease Drug
Zubiqo Take
"Handing over $355 million upfront for a drug that is only in Phase 2 trials proves that massive pharmaceutical players will pay almost any premium to buy their way into the lucrative rare disease market."
BullishMag 7
Reuters